| Identification | Back Directory | [Name]
JNJ 26483327 | [CAS]
807640-87-5 | [Synonyms]
BGB102
BGB-102
BGB 102
MTKi-327
EOS-60486
JNJ26483327
JNJ-26483327
JNJ 26483327
BGB102,BGB 102
17-Bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl-4,6-ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine
4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- | [Molecular Formula]
C22H25BrN4O2 | [MDL Number]
MFCD28386291 | [MOL File]
807640-87-5.mol | [Molecular Weight]
457.36 |
| Chemical Properties | Back Directory | [Boiling point ]
582.4±50.0 °C(Predicted) | [density ]
1.310±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
8.26±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BGB-102 is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively. | [in vivo]
JNJ-26483327 (75 mg/kg, p.o.) delays xenograft tumour growth compared to vehicle treatment, but when combines with Herceptin, they can abrogate the PKB feedback loop and is synergistic in inhibition of xenograft tumour growth[1]. | [IC 50]
EGFR: 9.6 nM (IC50); HER2: 18 nM (IC50); HER4: 40.3 nM (IC50) | [References]
[1] Gijsen M, et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 2010 Dec 21;8(12):e1000563. DOI:10.1371/journal.pbio.1000563 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|